Eric Abenojar Selected Research

pyrrolidin-3-yl-methanesulfonic acid (PMSA)

1/2022

Intracellular vesicle entrapment of nanobubble ultrasound contrast agents targeted to PSMA promotes prolonged enhancement and stability in vivo and in vitro.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Eric Abenojar Research Topics

Disease

10	Neoplasms (Cancer) 01/2024 - 01/2020
2	Prostatic Neoplasms (Prostate Cancer) 01/2021 - 01/2020
1	Hyperthermia 10/2021
1	Disease Progression 01/2020

Drug/Important Bio-Agent (IBA)

5	Contrast MediaIBA 01/2022 - 01/2020
2	LipidsIBA 01/2024 - 09/2023
2	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2024 - 09/2023
2	Biomarkers (Surrogate Marker)IBA 01/2022 - 02/2021
2	AntigensIBA 01/2022 - 01/2021
1	HydrogelsIBA 07/2022
1	1-phenyl-3,3-dimethyltriazene (PDT)IBA 01/2022
1	pyrrolidin-3-yl-methanesulfonic acid (PMSA)IBA 01/2022
1	Tumor Biomarkers (Tumor Markers)IBA 01/2022
1	CytokinesIBA 10/2021
1	Immune Checkpoint InhibitorsIBA 10/2021
1	Class 2 Receptor-Like Protein Tyrosine PhosphatasesIBA 02/2021

Therapy/Procedure

5	Microbubbles 01/2024 - 01/2020
2	Ultrasonic Therapy 01/2024 - 09/2023
2	Therapeutics 01/2022 - 01/2021
1	Radiotherapy 07/2022
1	Photochemotherapy (Photodynamic Therapy) 01/2022
1	Induced Hyperthermia (Thermotherapy) 10/2021
1	Precision Medicine 01/2020